Article

Perrigo buys ophthalmic portfolio of Fera Pharmaceuticals

Perrigo Co. has acquired the ophthalmic portfolio of Fera Pharmaceuticals, a Long Island, NY-based specialty pharmaceutical company, for an upfront payment of $93 million.

Allegan, MI-Perrigo Co. has acquired the ophthalmic portfolio of Fera Pharmaceuticals, a Long Island, NY-based specialty pharmaceutical company, for an upfront payment of $93 million.

Perrigo, a provider of health-care products, purchased the ophthalmic sterile ointment and solution product portfolio from Fera, including nine prescription ANDA products. The portfolio generated more than $30 million in net revenues in 2012.

“The ophthalmic category has been one of high strategic interest to Perrigo, as we continue to pursue opportunities that strengthen our leadership position within the niche prescription-extended topical space,” said Joseph C. Papa, chairman, president, and chief executive officer of Perrigo, in a prepared statement. “The breadth of the Fera portfolio allows us to become immediately relevant to patients and physicians across the country seeking cost-effective alternatives for the treatment of common ocular conditions.”

A packager of generic home remedies since 1887, Perrigo develops, manufactures, and distributes over-the-counter (OTC) and generic prescription pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, and active pharmaceutical ingredients. The company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. Perrigo’s primary markets and locations of operations include the United States, Israel, Mexico, the United Kingdom, India, China, and Australia.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.